Publication | Closed Access

Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells

Hematological MalignancyMedicinal ChemistryOncologyMedicineDna MethylationHistone DeacetylationPathologyPharmacotherapyAnti-cancer AgentPharmacologyPreclinical EvaluationCancer ResearchTumor BiologyMyeloid Neoplasia